ACET

Adicet Bio, Inc.

1.59 USD
-0.01 (-0.63%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Adicet Bio, Inc. stock is down -18.46% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 May’s closed higher than April. 100% of analysts rate it a buy.

About Adicet Bio, Inc.

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.